Reprogramming of the MicroRNA transcriptome mediates resistance to rapamycin

Journal of Biological Chemistry

Volumn 288, Issue 9, 2013, Pages 6034-6044

  Totary Jain, Hana ^a   Sanoudou, Despina ^b   Ben Dov, Iddo Z ^c   Dautriche, Cula N ^a   Guarnieri, Paolo ^d   Marx, Steven O ^e   Tuschl, Thomas ^c   Marks, Andrew R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ROCKEFELLER UNIVERSITY   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR AGENTS; DOWN-REGULATION; DOWNSTREAM COMPONENTS; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); MECHANISMS OF RESISTANCES; MICRORNAS; MIRNA EXPRESSIONS; RAPAMYCIN; RAPAMYCIN TREATMENT; THERAPEUTIC TARGETS; TRANSCRIPTOMES; TUMOR SUPPRESSORS; TUMORIGENESIS; UP-REGULATION;

ANTIBIOTICS; CELL PROLIFERATION; RNA;

TUMORS;

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 10A; MICRORNA 125B; MICRORNA 143; MICRORNA 17; MICRORNA 18A; MICRORNA 19A; MICRORNA 19B; MICRORNA 20A; MICRORNA 20B; MICRORNA 21; MICRORNA 22; MICRORNA 222; MICRORNA 29A; MICRORNA 29B; MICRORNA 370; MICRORNA 3756; MICRORNA 667; MICRORNA 675; MICRORNA 93; RAPAMYCIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENE CLUSTER; GENETIC REGULATION; MOUSE; NONHUMAN; ONCOGENE; PHARMACOGENETICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICRORNAS; NEOPLASM PROTEINS; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84874774756     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.416446     Document Type: Article

References (69)

1. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument- Bromage, H., Tempst, P., and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175
2. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument- Bromage, H., Tempst, P., and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
3. Sabatini, D. M. (2006)mTORand cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734
4. Sarbassov, D. D., Ali, S. M., and Sabatini, D. M. (2005) Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603
5. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
6. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., Massague, J., Crabtree, G. R., and Roberts, J. M. (1994) Interleukin-2- mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570-573
7. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
8. Vivanco, I., and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501
9. David, O., Jett, J., LeBeau, H., Dy, G., Hughes, J., Friedman, M., and Brody, A. R. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 10, 6865-6871
10. De Benedetti, A., and Graff, J. R. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199
11. Faivre, S., Kroemer, G., and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688
12. Bjornsti, M. A., and Houghton, P. J. (2004) The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348
13. Chan, S. (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 91, 1420-1424
14. Totary-Jain, H., Sanoudou, D., Dautriche, C. N., Schneller, H., Zambrana, L., and Marks, A. R. (2012) Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 72, 1836-1843
15. Dowling, R. J., Pollak, M., and Sonenberg, N. (2009) Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23, 77-91
16. Wysocki, P. J. (2009) mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 9, 231-241
17. Mita, M., Sankhala, K., Abdel-Karim, I., Mita, A., and Giles, F. (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Investig. Drugs 17, 1947-1954
18. Gridelli, C., Maione, P., and Rossi, A. (2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13, 139-147
19. Chan, J. A., and Kulke, M. H. (2009) Progress in the treatment of neuroendocrine tumors. Curr. Oncol. Rep 11, 193-199
20. Treiber, G. (2009) mTOR inhibitors for hepatocellular cancer: a forwardmoving target. Expert Rev. Anticancer Ther. 9, 247-261
21. Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson, A. B., 3rd, Burstein, H. J., Ettinger, D. S., Febbo, P. G., Fury, M. G., Hudes, G. R., Kies, M. S., Kwak, E. L., Morgan, R. J., Jr., Mortimer, J., Reckamp, K., Venook, A. P., Worden, F., and Yen, Y. (2008) NCCN task force report: mTOR inhibition in solid tumors. J. Natl. Compr. Canc. Netw. 6, Suppl. 5, S1-S20
22. Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., Sauerbrei, E., Mishaeli, M., Huntsman, D., Walsh, W., Olivo, M., McIntosh, L., and Seymour, L. (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. J. Clin. Oncol. 27, 4536-4541
23. Atkins, M. B., Yasothan, U., and Kirkpatrick, P. (2009) Everolimus. Nat. Rev. Drug Discov. 8, 535-536
24. Aoki, M., Blazek, E., and Vogt, P. K. (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. U.S.A. 98, 136-141
25. Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S. M., Kwiatkowski, D., and Lane, H. A. (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor-dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8, 742-753
26. Lee, Y., Kim, M., Han, J., Yeom, K. H., Lee, S., Baek, S. H., and Kim, V. N. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060
27. Borchert, G. M., Lanier, W., and Davidson, B. L. (2006) RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 13, 1097-1101
28. He, L., and Hannon, G. J. (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531
29. Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H., Nonaka, D., Li, J., Spector, Y., Rosenfeld, N., Chajut, A., Cohen, D., Aharonov, R., and Mansukhani, M. (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27, 2030-2037
30. Osaki, M., Takeshita, F., and Ochiya, T. (2008) MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 13, 658-670
31. Mayer, C., and Grummt, I. (2006) Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 25, 6384-6391
32. Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., and Marks, A. R. (1996) Rapamycin resistance tied to defective regulation of p27Kip1. Mol. Cell. Biol. 16, 6744-6751
33. Ray, J. L., Leach, R., Herbert, J. M., and Benson, M. (2001) Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 23, 185-188
34. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A. J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J. Y., and Zhang, J. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80
35. Ritchie, M. E., Silver, J., Oshlack, A., Holmes, M., Diyagama, D., Holloway, A., and Smyth, G. K. (2007) A comparison of background correction methods for two-colour microarrays. Bioinformatics 23, 2700-2707
36. Silver, J. D., Ritchie, M. E., and Smyth, G. K. (2009) Microarray background correction: maximum likelihood estimation for the normal-exponential convolution. Biostatistics 10, 352-363
37. Yang, Y. H., Dudoit, S., Luu, P., Lin, D. M., Peng, V., Ngai, J., and Speed, T. P. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30, e15
38. Benjamini, Y. H., Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289-300
39. Wu, Z., and Irizarry, R. A. (2005) Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J. Comput. Biol. 12, 882-893
40. Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20
41. Marx, S. O., and Marks, A. R. (1999) Cell cycle progression and proliferation despite 4BP-1 dephosphorylation. Mol. Cell. Biol. 19, 6041-6047
42. Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C., and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200-216
43. Slavik, J. M., Lim, D. G., Burakoff, S. J., and Hafler, D. A. (2001) Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes. J. Immunol. 166, 3201-3209
44. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., and Rosen, N. (2006) mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508
45. Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., and Thomas, G. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205
46. Olive, V., Bennett, M. J., Walker, J. C., Ma, C., Jiang, I., Cordon-Cardo, C., Li, Q. J., Lowe, S. W., Hannon, G. J., and He, L. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23, 2839-2849
47. Mavrakis, K. J., Leslie, C. S., and Wendel, H. G. (2011) Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle 10, 2845-2849
48. He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and Hammond, S. M. (2005) A microRNA polycistron as a potential human oncogene. Nature 435, 828-833
49. Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., Cai, X., Wang, K., Wang, G., Ba, Y., Zhu, L., Wang, J., Yang, R., Zhang, Y., Ren, Z., Zen, K., Zhang, J., and Zhang, C. Y. (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28, 1385-1392
50. Xiong, J., Du, Q., and Liang, Z. (2010) Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 29, 4980-4988
51. Havelange, V., Garzon, R., and Croce, C. M. (2009) MicroRNAs: new players in acute myeloid leukaemia. Br. J. Cancer 101, 743-748
52. Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., Rothballer, A., Ascano, M., Jr., Jungkamp, A. C., Munschauer, M., Ulrich, A., Wardle, G. S., Dewell, S., Zavolan, M., and Tuschl, T. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141, 129-141
53. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843
54. Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas-Tikhonenko, A., and Mendell, J. T. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 40, 43-50
55. Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., and Thomas-Tikhonenko, A. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065
56. Mestdagh, P., Bostrom, A. K., Impens, F., Fredlund, E., Van Peer, G., De Antonellis, P., von Stedingk, K., Ghesquiere, B., Schulte, S., Dews, M., Thomas-Tikhonenko, A., Schulte, J. H., Zollo, M., Schramm, A., Gevaert, K., Axelson, H., Speleman, F., and Vandesompele, J. (2010) The miR- 17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol. Cell 40, 762-773
57. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., and Mesirov, J. P. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550
58. John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., and Marks, D. S. (2004) Human MicroRNA targets. PLoS Biol. 2, e363
59. Gaidatzis, D., van Nimwegen, E., Hausser, J., and Zavolan, M. (2007) Inference of miRNA targets using evolutionary conservation and pathway analysis. BMC Bioinformatics 8, 69
60. Balakumaran, B. S., Porrello, A., Hsu, D. S., Glover, W., Foye, A., Leung, J. Y., Sullivan, B. A., Hahn, W. C., Loda, M., and Febbo, P. G. (2009) MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 69, 7803-7810
61. Trabucchi, M., Briata, P., Garcia-Mayoral, M., Haase, A. D., Filipowicz, W., Ramos, A., Gherzi, R., and Rosenfeld, M. G. (2009) The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 459, 1010-1014
62. Briata, P., Lin, W. J., Giovarelli, M., Pasero, M., Chou, C. F., Trabucchi, M., Rosenfeld, M. G., Chen, C. Y., and Gherzi, R. PI3K/AKT signaling determines a dynamic switch between distinct KSRP functions favoring skeletal myogenesis. Cell Death Differ. 19, 478-487
63. Gherzi, R., Trabucchi, M., Ponassi, M., Ruggiero, T., Corte, G., Moroni, C., Chen, C. Y., Khabar, K. S., Andersen, J. S., and Briata, P. (2006) The RNAbinding protein KSRP promotes decay of β-catenin mRNA and is inactivated by PI3K-AKT signaling. PLoS Biol. 5, e5
64. Sampson, V. B., Rong, N. H., Han, J., Yang, Q., Aris, V., Soteropoulos, P., Petrelli, N. J., Dunn, S. P., and Krueger, L. J. (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67, 9762-9770
65. Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., eVere White, R. W., Kung, H. J., Evans, C. P., and Gao, A. C. (2012) MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J. Biol. Chem. 287, 1527-1537
66. Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., and Slack, F. J. (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759-764
67. Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., Chin, L., Brown, D., and Slack, F. J. (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67, 7713-7722
68. Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., and Slack, F. J. (2005) RAS is regulated by the let-7 microRNA family. Cell 120, 635-647
69. Mayr, C., Hemann, M. T., and Bartel, D. P. (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579